The development of ABL tyrosine kinase inhibitors that were originated against the oncogenic BCR-ABL protein for the treatment of chronic myeloid leukemia (CML) is the most successful example of molecular targeted therapy to date. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.